Uncategorized

National Medicare coverage paves the way for a larger patient population to access the blood pressure treatment, which gained FDA approval in 2023.

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in Sjögren’s disease, the pharma reported at the American College of Rheumatology Convergence congress on Wednesday.

More than 60% of respondents said insurance companies are most at fault for medical debt, compared with just 9% who blamed hospitals, according to a survey by nonprofit Undue Medical Debt.

The purchase is expected to complement Thermo’s clinical research services, as companies are conducting more clinical trials.

Genentech is letting go of 118 employees in San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.

The operator increased its outlook after posting earnings growth in the third quarter, aided by strong demand for services in its acute business and a newly approved Medicaid state supplemental payment program.

Already sky high after the success of its limb-girdle muscular dystrophy therapy, reported on Monday, BridgeBio’s shares rose nearly 8% more as encaleret balanced calcium levels in patients with a genetic thyroid disorder.

Shingrix sales in the U.S. took a 15% dive in the third quarter. GSK is now the second Big Pharma to report declining vaccine sales, after Sanofi reported a similar decline last week.

El yacimiento arqueológico de Casas del Turuñuelo (Guareña, Badajoz, España) destaca por el relevante papel que tuvo este asentamiento en el comercio mediterráneo durante la época tartésica, en el siglo V antes de Cristo.   En dicho yacimiento, …

The reprioritization initiative extends Aldeyra’s cash runway into the second half of 2027.